Biosimilars Unveiled: Current Trends, Challenges, and Future Opportunities in the US Marketplace : Episode 6
Opinion
Video
Economic Impacts and Pricing Strategies Surrounding Biosimilars
The panel discusses the economic impact biosimilars have across different patient types.
Video Player is loading.
Video content above is prompted by the following:
- What economic impacts do biosimilars have in different delivery channels (inpatient, self-administered outpatient, outpatient infusion)?
- How do pricing strategies for biosimilars, such as the high and low list prices of adalimumab biosimilars, affect their market penetration and adoption?
- How do biosimilar pricing strategies affect patient access and affordability?
- Are there more effective pricing models that could be adopted?
- Are there certain customer subtypes that will want a rebate drive model vs. those want a rebate driven model vs. a WAC driven model?
Related Videos
Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?
Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Emerging Therapeutic Areas for Bispecific Antibodies
Payer and Reimbursement Considerations for Bispecific Therapies
Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration
Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
Optimizing Bispecific Antibody Administration With EHR and Technology Solutions
Overcoming Access Challenges
Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations
Related Content
